Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Other Revenue	-	0.08	1.03	1.14	-
Revenue	-	0.08	1.03	1.14	-
Revenue Growth (YoY)	-	-92.14%	-9.96%	-	-
Gross Profit	-	0.08	1.03	1.14	-
Selling, General & Admin	12.08	13.33	12	8.08	6.31
Research & Development	30.05	38.67	23.14	18.03	16.09
Operating Expenses	42.12	52	35.13	26.11	22.39
Operating Income	-42.12	-51.92	-34.1	-24.96	-22.39
Interest & Investment Income	3.88	3.1	1.09	0.19	0.18
Pretax Income	-38.24	-48.82	-33.02	-24.77	-22.22
Net Income	-38.24	-48.82	-33.02	-24.77	-22.22
Preferred Dividends & Other Adjustments	-	-	-	-	0
Net Income to Common	-38.24	-48.82	-33.02	-24.77	-22.22
Shares Outstanding (Basic)	30	27	24	21	12
Shares Outstanding (Diluted)	30	27	24	21	12
Shares Change (YoY)	13.03%	10.20%	17.37%	69.51%	143.87%
EPS (Basic)	-1.27	-1.83	-1.37	-1.20	-1.83
EPS (Diluted)	-1.27	-1.83	-1.37	-1.20	-1.83
Free Cash Flow	-33.08	-47.49	8.28	-21	-21.87
Free Cash Flow Per Share	-1.10	-1.78	0.34	-1.02	-1.80
Gross Margin	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-64098.76%	-3311.07%	-2182.17%	-
Profit Margin	-	-60269.14%	-3205.53%	-2165.56%	-
Free Cash Flow Margin	-	-58627.16%	803.69%	-1835.58%	-
EBITDA	-41.91	-51.71	-33.9	-24.78	-22.26
D&A For EBITDA	0.21	0.21	0.21	0.19	0.14
EBIT	-42.12	-51.92	-34.1	-24.96	-22.39
Revenue as Reported	-	0.08	1.03	1.14	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q